{"id":"35e3fec41fcb","type":"article","url":"https://hartvaat.nl/2021/10/01/uitgebreide-vasodilatatie-en-qol-bij-acuut-hf-substudie/","title":"Uitgebreide vasodilatatie en QoL bij acuut HF: substudie","title_en":"Effect of a strategy of comprehensive vasodilation versus usual care on health-related quality of life among patients with acute heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","aperitif-trial","bloeddrukbehandeling","dapa-hf","sacubitril-valsartan"],"journal":"ESC heart failure","doi":"10.1002/ehf2.13543","source_url":"https://doi.org/10.1002/ehf2.13543","authors":["Maria Belkin","Desiree Wussler","Danielle Menosi Gualandro","Samyut Shrestha","Ivo Strebel","Assen Goudev","Micha T Maeder","Joan Walter","Dayana Flores","Nikola Kozhuharov","Pedro Lopez-Ayala","Isabelle Danier","Mucio Tavares de Oliveira Junior","Richard Kobza","Hans Rickli","Tobias Breidthardt","Paul Erne","Thomas Münzel","Christian Mueller"],"significance":5,"published":"2021-10-01","source_date":"2021-10-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This quality-of-life substudy showed that a comprehensive vasodilation strategy versus usual care in acute heart failure does not improve long-term health-related quality of life, consistent with the neutral primary endpoint.","created":"2026-07-03T10:29:25Z","updated":"2026-07-03T13:28:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"QoL-substudie van de uitgebreide vasodilatiestrategie versus standaardzorg bij acuut hartfalen.","abstract_original":"AIMS: We aimed to assess the long-term effect of a strategy of comprehensive vasodilation versus usual care on health-related quality of life (HRQL) among patients with acute heart failure (AHF). METHODS AND RESULTS: Health-related quality of life was prospectively assessed by the generic 3-levelled EQ-5D and the disease-specific Kansas City Cardiomyopathy Questionnaire (KCCQ) among adult AHF patients enrolled in an international, multicentre, randomised, open-label blinded-end-point trial of a strategy that emphasized early intensive and sustained vasodilation using maximally tolerated doses of established oral and transdermal vasodilators according to systolic blood pressure. Changes in EQ-5D and KCCQ from admission to 180 day follow-up were individually compared between the intensive vasodilatation and the usual care group. Among 666 patients eligible for 180 day follow-up, 284 (43%, median age 79 years, 35% women) and 198 (30%, median age 77 years, 35% women) had completed the EQ-5D and KCCQ at baseline and follow-up, respectively. There was a significant improvement in HRQL as quantified by both, EQ-5D and KCCQ, from hospitalization to 180 day follow-up, with no significant differences in the change of HRQL between both treatment strategies. For instance, 39 (26%) versus 33 (25%) patients had an improvement by at least one level in at least two categories in the EQ-5D. Median increase in KCCQ overall summary score (KCCQ-OSS) was 17.6 (IQR 2.0-42.6) in the intervention group versus 18.5 (IQR 3.9-39.3) in the usual care group (P < 0.001 vs. baseline, P = 0.945 between groups). CONCLUSIONS: Among patients with AHF, long-term HRQL quantified by EQ-5D and KCCQ improved substantially, with overall no significant differences between a strategy of comprehensive vasodilation versus usual care."}